Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

Bell JA, Galaznik A, Pompilus F, Strzok S, Bejar R, Scipione F, Fram RJ, Faller DV, Cano S, Marquis P.

J Patient Rep Outcomes. 2019 Jun 19;3(1):35. doi: 10.1186/s41687-019-0123-4.

2.

A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.

Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota VK.

Leuk Res. 2019 Mar;78:45-51. doi: 10.1016/j.leukres.2019.01.008. Epub 2019 Jan 24.

3.

Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.

Bell JA, Galaznik A, Blazer M, Shih HC, Farrelly E, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV.

Pharmacoecon Open. 2019 Jun;3(2):237-245. doi: 10.1007/s41669-018-0100-5.

4.

Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.

Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota V.

Leuk Res. 2018 Aug;71:27-33. doi: 10.1016/j.leukres.2018.06.010. Epub 2018 Jun 18.

5.

Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care.

Bell JA, Galaznik A, Blazer M, Farrelly E, Ogbonnaya A, Raju A, Eaddy M, Fram RJ, Faller DV.

Leuk Lymphoma. 2019 Jan;60(1):49-59. doi: 10.1080/10428194.2018.1464155. Epub 2018 Jun 22.

PMID:
29932781
6.

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review.

Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):e303-e314. doi: 10.1016/j.clml.2018.05.003. Epub 2018 May 10.

7.

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.

Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):e157-e166. doi: 10.1016/j.clml.2018.02.001. Epub 2018 Feb 8.

8.

Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.

Walsh MD, Hanna SK, Sen J, Rawal S, Cabral CB, Yurkovetskiy AV, Fram RJ, Lowinger TB, Zamboni WC.

Clin Cancer Res. 2012 May 1;18(9):2591-602. doi: 10.1158/1078-0432.CCR-11-1554. Epub 2012 Mar 5.

9.

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.

Yurkovetskiy AV, Fram RJ.

Adv Drug Deliv Rev. 2009 Nov 12;61(13):1193-202. doi: 10.1016/j.addr.2009.01.007. Epub 2009 Aug 12. Review.

PMID:
19682517
10.

Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.

Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP Jr.

Clin Cancer Res. 2005 Nov 1;11(21):7825-33.

11.

A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.

Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA.

Clin Cancer Res. 2005 Nov 1;11(21):7807-16.

12.

Bone metastases.

Hamdalla H, Fram RJ.

Med Health R I. 2000 Apr;83(4):112-3. No abstract available.

PMID:
10821011
13.

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.

Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, Fram RJ, Van Echo DA.

Clin Cancer Res. 1998 Mar;4(3):629-34.

14.

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.

Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ.

Cancer. 1994 Dec 1;74(11):2949-55.

PMID:
7525038
15.

Cisplatin and platinum analogues: recent advances.

Fram RJ.

Curr Opin Oncol. 1992 Dec;4(6):1073-9. Review.

PMID:
1457521
16.

Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial.

Recht L, Fram RJ, Strauss G, Fitzgerald TJ, Liepman M, Lew R, Kadish S, Sherman D, Wilson J, Greenberger J, et al.

Am J Clin Oncol. 1990 Apr;13(2):125-31.

PMID:
2156417
17.

Mechanisms underlying resistance to streptozotocin in Mer+ and Mer- human tumor lines.

Fram RJ, Robichaud N.

Biochem Pharmacol. 1990 Mar 1;39(5):959-64.

PMID:
2155617
18.

Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.

Fram RJ, Woda BA, Wilson JM, Robichaud N.

Cancer Res. 1990 Jan 1;50(1):72-7.

PMID:
2293559
19.

Schedule dependence of buthionine sulfoximine in reversing resistance to cisplatin.

Robichaud NJ, Fram RJ.

Chem Biol Interact. 1990;76(3):333-42.

PMID:
2225234
20.

DNA repair mechanisms affecting cytotoxicity by streptozotocin in E. coli.

Fram RJ, Mack SL, George M, Marinus MG.

Mutat Res. 1989 Sep;218(2):125-33.

PMID:
2475773
21.

Sequence specificity of streptozotocin-induced mutations.

Mack SL, Fram RJ, Marinus MG.

Nucleic Acids Res. 1988 Oct 25;16(20):9811-20.

22.
23.

Gene expression in E. coli after treatment with streptozotocin.

Fram RJ, Marinus MG, Volkert MR.

Mutat Res. 1988 Mar;198(1):45-51.

PMID:
2965298
24.
25.

Potentiation of ara-C induced cytotoxicity by hydroxyurea in LoVo colon carcinoma cells.

Robichaud NJ, Fram RJ.

Biochem Pharmacol. 1987 May 15;36(10):1673-7.

PMID:
3109427
26.

A comparison of the effects of cytosine arabinoside and beta-lactams on DNA synthesis and cellular proliferation.

Fram RJ.

Cell Biol Toxicol. 1986 Dec;2(4):531-9. Review. No abstract available.

PMID:
3077085
28.

Studies on mutagenesis and repair induced by platinum analogs.

Fram RJ, Cusick PS, Marinus MG.

Mutat Res. 1986 Jan;173(1):13-8.

PMID:
3510378
29.
30.

Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage.

Fram RJ, Cusick PS, Wilson JM, Marinus MG.

Mol Pharmacol. 1985 Jul;28(1):51-5.

PMID:
3894930
31.

Inhibition of DNA excision repair and the repair of X-ray-induced DNA damage by cytosine arabinoside and hydroxyurea.

Fram RJ, Kufe DW.

Pharmacol Ther. 1985;31(3):165-76. No abstract available.

PMID:
3939629
32.

Lethal effects of 1-beta-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair.

Kufe DW, Weichselbaum R, Egan EM, Dahlberg W, Fram RJ.

Mol Pharmacol. 1984 Mar;25(2):322-6.

PMID:
6700578
33.

The effect of inhibitors of DNA synthesis on DNA repair.

Fram RJ, Kufe DW.

Nucleic Acids Symp Ser. 1984;(13):95-107. No abstract available.

PMID:
6436789
34.
35.
36.
38.

Genetic control of ligand-induced events in B lymphocytes.

Fram RJ, Sidman CL, Unanue ER.

J Immunol. 1976 Nov;117(5 Pt 1):1456-63.

PMID:
794411

Supplemental Content

Support Center